NASDAQ:AKCA
Delisted
Akcea Therapeutics, Inc. Stock News
$18.17
+0 (+0%)
At Close: May 27, 2022
Akcea Therapeutics (AKCA) Reports Q1 Loss, Misses Revenue Estimates
10:45pm, Tuesday, 05'th May 2020
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Akcea Reports Financial Results and Highlights for First Quarter 2020
08:05pm, Tuesday, 05'th May 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
NEW YORK, NY / ACCESSWIRE / May 4, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
NEW YORK, NY / ACCESSWIRE / May 1, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
NEW YORK, NY / ACCESSWIRE / April 30, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on beha
NEW YORK, NY / ACCESSWIRE / April 30, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on beha
New York, New York--(Newsfile Corp. - April 29, 2020) - Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty cla
NEW YORK, NY / ACCESSWIRE / April 29, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on beha
Zacks Investment Research Upgrades Akcea Therapeutics (NASDAQ:AKCA) to Hold
09:18am, Wednesday, 29'th Apr 2020
Akcea Therapeutics (NASDAQ:AKCA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks.com reports. Accordin
NEW YORK, NY / ACCESSWIRE / April 28, 2020 / Labaton Sucharow LLP, a leading and award-winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on beha
Earnings Preview: Akcea Therapeutics (AKCA) Q1 Earnings Expected to Decline
04:34pm, Tuesday, 28'th Apr 2020
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Akcea Therapeutics (AKCA) Q1 Earnings Expected to Decline
04:34pm, Tuesday, 28'th Apr 2020
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
